Movano Health Announces Blood Pressure Partnership Forum Following Significant Response To Accuracy Achievement
Portfolio Pulse from Benzinga Newsdesk
Movano Health (NASDAQ:MOVE) has announced a blood pressure partnership forum following positive results from its blood pressure clinical trial. The company will demonstrate its System on a Chip (SoC) technology at the 2024 CES Show and the JP Morgan Healthcare Conference. The SoC technology, which has been in development for five years, can monitor multiple chronic conditions and has achieved an FDA-recognized accuracy standard for cuffless blood pressure devices. Movano Health is also exploring AI-based calibration to improve device performance. The company's Evie Ring already offers a suite of health monitoring features, and the addition of blood pressure monitoring is expected to enhance its capabilities.
December 12, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Movano Health's successful blood pressure clinical trial and upcoming demonstrations of its SoC technology at major events may attract potential partners and accelerate development and commercialization.
The positive clinical trial results and the planned demonstrations at high-profile conferences are likely to generate investor interest and could lead to potential partnerships, which may positively impact Movano Health's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100